Find a TenderAwarded
Published 21 Jun 2021, 11:23 BST

Official UK procurement notice

NHS National Generic Pharmaceuticals Wave 13

Official notice

Authority: The NHS Commissioning Board (operating under the name of NHS England) (NHS & healthcare)

Framework agreement3 lotsGoodsOpen procedure
Sectors: Medical Devices & Pharma (33) Delivery: UK
Framework ceiling (notional)£1,637,875,080total for 3 lots · framework ceiling, not attributable revenue
Submissions closed 26 Jul 2021awarded 30 Dec 2021
Lots 3see the lot list below

What is being bought3 lots · detail below

Published requirement description

Potential periods of call-offs under the framework agreement:<br/><br/>Transition (Everolimus)<br/>CESW: 1 March 2022 – 30 September 2023 (19 months)<br/>LSNE: 1 March 2022 – 31 January 2023 (11 months)<br/>NWLN: 1 March 2022 – 31 January 2023 (11 months)<br/><br/>Oral Products plus non-parenterals<br/>All Regions: 1 March 2022 - 31 May 2024 (27 months)<br/><br/>Hospital Only Products<br/>CESW: 1 February 2022 – 30 September 2023 (20 months)<br/>LSNE: 1 February 2022 – 31 May 2024 (28 months)<br/>NWLN: 1 February 2022 – 31 January 2023 (12 months)

CPV: Pharmaceutical products

How this framework works

From the published notice
Bids received
124 bids on the busiest of 3 lots · 131 suppliers appointed

Lots and requirements (3)Procurement structure

3 lots · no lot values published
Lot #1CM/PHG/17/5532/00 Transition (Everolimus)Awarded

Invitation to offer for NHS National Generic Pharmaceuticals Wave 13<br/>Offer reference number: CM/PHG/17/5532<br/>Period of framework agreement: The total maximum duration of the framework agreement to be no more than 28 months, with an option or options to extend (at the Authority’s sole discretion) for a period or periods up to a total of 48 months.<br/><br/>Potential periods of call-offs under the framework agreement:<br/><br/>Transition (Everolimus)<br/>CESW: 1 March 2022 – 30 September 2023 (19 months)<br/>LSNE: 1 March 2022 – 31 January 2023 (11 months)<br/>NWLN: 1 March 2022 – 31 January 2023 (11 months)<br/><br/>Oral Products plus non-parenterals<br/>All Regions: 1 March 2022 - 31 May 2024 (27 months)<br/><br/>Hospital Only Products<br/>CESW: 1 February 2022 – 30 September 2023 (20 months)<br/>LSNE: 1 February 2022 – 31 May 2024 (28 months)<br/>NWLN: 1 February 2022 – 31 January 2023 (12 months) Additional information: Price is not the only award criterion and all criteria are stated only in the procurement documents

Delivery: UK · Please refer to document 03, schedule 8 in the ITO documents for the list of Purchasing Points
Extensions: Option or options to extend (at the Authority’s sole discretion) for a period or periods up to a total of 48 months.Variant bids: not allowed
Lot #2CM/PHG/17/5532/01 Oral Products plus non-parenteralsAwarded

Invitation to offer for NHS National Generic Pharmaceuticals Wave 13<br/>Offer reference number: CM/PHG/17/5532<br/>Period of framework agreement:The total maximum duration of the framework agreement to be no more than 28 months, with an option or options to extend (at the Authority’s sole discretion) for a period or periods up to a total of 48 months.<br/><br/>Potential periods of call-offs under the framework agreement:<br/><br/>Transition (Everolimus)<br/>CESW: 1 March 2022 – 30 September 2023 (19 months)<br/>LSNE: 1 March 2022 – 31 January 2023 (11 months)<br/>NWLN: 1 March 2022 – 31 January 2023 (11 months)<br/><br/>Oral Products plus non-parenterals<br/>All Regions: 1 March 2022 - 31 May 2024 (27 months)<br/><br/>Hospital Only Products<br/>CESW: 1 February 2022 – 30 September 2023 (20 months)<br/>LSNE: 1 February 2022 – 31 May 2024 (28 months)<br/>NWLN: 1 February 2022 – 31 January 2023 (12 months) Additional information: Price is not the only award criterion and all criteria are stated only in the procurement documents

Delivery: UK · Please refer to document 03, schedule 8 in the ITO documents for the list of Purchasing Points
Extensions: Option or options to extend (at the Authority’s sole discretion) for a period or periods up to a total of 48 months.Variant bids: not allowed
Lot #3CM/PHG/17/5532/02 Hospital Only ProductsAwarded

Invitation to offer for NHS National Generic Pharmaceuticals Wave 13<br/>Offer reference number: CM/PHG/17/5532<br/>Period of framework agreement: The total maximum duration of the framework agreement to be no more than 28 months, with an option or options to extend (at the Authority’s sole discretion) for a period or periods up to a total of 48 months.<br/><br/>Potential periods of call-offs under the framework agreement:<br/><br/>Transition (Everolimus)<br/>CESW: 1 March 2022 – 30 September 2023 (19 months)<br/>LSNE: 1 March 2022 – 31 January 2023 (11 months)<br/>NWLN: 1 March 2022 – 31 January 2023 (11 months)<br/><br/>Oral Products plus non-parenterals<br/>All Regions: 1 March 2022 - 31 May 2024 (27 months)<br/><br/>Hospital Only Products<br/>CESW: 1 February 2022 – 30 September 2023 (20 months)<br/>LSNE: 1 February 2022 – 31 May 2024 (28 months)<br/>NWLN: 1 February 2022 – 31 January 2023 (12 months) Additional information: Price is not the only award criterion and all criteria are stated only in the procurement documents

Delivery: UK · Please refer to document 03, schedule 8 in the ITO documents for the list of Purchasing Points
Extensions: Option or options to extend (at the Authority’s sole discretion) for a period or periods up to a total of 48 months.Variant bids: not allowed

What it takes to win
i

How this buyer will score bids.

The evaluation criteria and weights exactly as published on the notice, grouped by family (price, quality, social value and so on).

Evaluation split and conditions of participation as published; the tender pack may add more
What this means for your bid
  • “NHS National Generic Pharmaceuticals Wave 13” is a framework: the contest is a place on its panel, not a single contract.

Procedure terms & legal framework

From the official record · publisher note attached
Procedure method
Open procedure
Legal basis
CELEX · 32014L0024 Public Contracts Regulations 2015 (Directive 2014/24/EU)
Procurement category
Goods
Notice status
Awarded
Procurement threshold
Unspecified in notice
Regulatory regime
Standard
Commercial structure
Framework agreement
Who may use this agreement
Not stated in the notice; call-off rights may be limited to the establishing authority
Competition type
Competitive procedure
GPA / WTO covered
Yes (GPA)
Recurring procurement
No (one-off requirement)
First published
21 Jun 2021, 11:23 BST
Last source update
14 Jan 2022, 10:31 GMT
Award evaluation window
26 Jul 2021 – …
Authority reference
CM/PHG/17/5532
FTS notice number
2022/S 000-001128
Classification (CPV)
Pharmaceutical products
Delivery area
UK
Official registry OCID
ocds-h6vhtk-02be28 Find a Tender
Contract terms
Electronic trading
e-invoicing allowed · electronic ordering · electronic payment
Performance terms

See KPIs in procurement documents

Publisher note: RESPONDING TO THIS NOTICE;Any supplier may be disqualified who does not respond to the following in the requisite manner:1) Submission of expression of interest and procurement specific information. This procurement exercise will be conducted on the eTendering portal at http://health.atamis.co.ukCandidates wishing to be considered for this procurement exercise must register, and provide additional procurement specific information (if requested) through the eTendering portal as follows:1.1) If not already registered, Candidates should register on the eTendering portal at http://health.atamis.co.uk and click the link to register:- agree to the user agreement- populate company details1.2) Once registered, candidates must register interest as follows:- log to the portal- select "Find Opportunities" from the supplier home screen, use the "Sort by:" facility to find this opportunity and select the bold blue title to select- review opportunity details and click "Register Interest"- as you select the opportunity, you can review documents, send clarification messages, submit the response or decline to respond (if you decide not to participate in the opportunity)1.3) There is a supplier user guide on using the system and Candidates can contact the Atamis helpdesk at [email protected] or by calling 0800 9956035 for technical assistance when completing responses.2) General supplier information.To manage and assess supplier information the Contracting Authority requests candidates provide theircompany profile in the Government's Supplier Registration Service (which has replaced sid4gov), as follows:2.1) If not already registered (the previous sid4gov password, login and details will stillbe on the system), candidates must go to the following web page https://supplierregistration.cabinetoffice.gov.ukand select "Register" at the top of the page.Key in details as requested to search for your company. If you do not have a D-U-N-S® Number, click on the link at the right of the page to obtain a number from D&B.Candidates must obtain a Dun & Bradstreet (D&B) D-U-N-S® Number to enable registration on the system.2.2) Once registration is complete you are able to create and update your company profile. Candidates should ensure all the mandatory fields of their profile are completed and up to date for each procurement exercise.D&B data will be supplied automatically by D&B.2.3) For further help or information concerning this telephone +44 (0) 161 413 7982 or via themessage function on the website.OTHER CONTRACTING AUTHORITIESThe framework agreement is for the benefit of other participating NHS bodies (whether acting individually, or on behalf of, or together as members of any consortia) along with any other non-NHS bodies which the participants deem necessary for the delivery of services or goods to NHS bodies, local authorities, other government departments or non-departmental public bodies charged with the delivery of healthcare or health related services.

How it was run

Official notice
Run through: Atamis (Health Family) · Who buys & how to bid on Atamis
Supplier login requiredLanguage: EN
Access & registration note: Free · one account PER buying organisation portal · password resets come "from Salesforce.com" (check spam)

Tender documents are also served through a separate tool: http://health.atamis.co.uk ↗

Appointment period ends
26 Jul 2021, 13:00 BST
Submission channel
{"electronicSubmission","written"}
Accepted languages
en
Bid validity
90 days from the deadline
Bids opened
26 Jul 2021, 13:00 BST
Detailed submission instructions & authority contactsFrom official release

Timeline

26 Jul 2021 → 14 Jan 2022 · 3 dates
  1. Admission / appointment period endsperiod end, not a bid countdown
    26 Jul 2021, 13:00 BST
  2. Bids opened
    26 Jul 2021, 13:00 BST
  3. Notice published
    14 Jan 2022, 10:31 GMT

Notice history

1 event · 2 releases on Find a Tender
  1. Status changed to complete
    14 Jan 2022, 10:31 GMT

Commercial outcome & contract awards

Published awards, contracts and bid statistics, not a forecast
Suppliers appointed 131admitted to the panel · see the list ↓
Bids received 124busiest of 3 lots
Contracts signed 20latest 30 Dec 2021

192 suppliers are admitted to this framework without individual award values or dates, see the supplier list below.

Contracts

All 20 of these contracts carry the same published figure, £1, the framework's maximum for the whole notice, not each contract's own value. They are not eleven separate sums.

  • Lot 1 - CM/PHG/17/5532/00 Transition (Everolimus)

    Signed
    30 Dec 2021
    Value
    ceiling above
    Status
    active
  • Lot 1 - CM/PHG/17/5532/00 Transition (Everolimus)

    Signed
    30 Dec 2021
    Value
    ceiling above
    Status
    active
  • Lot 1 - CM/PHG/17/5532/00 Transition (Everolimus)

    Signed
    30 Dec 2021
    Value
    ceiling above
    Status
    active
  • Lot 1 - CM/PHG/17/5532/00 Transition (Everolimus)

    Signed
    30 Dec 2021
    Value
    ceiling above
    Status
    active
  • Lot 1 - CM/PHG/17/5532/00 Transition (Everolimus)

    Signed
    30 Dec 2021
    Value
    ceiling above
    Status
    active
  • Lot 2 - CM/PHG/17/5532/01 Oral Products plus non-parenterals

    Signed
    30 Nov 2021
    Value
    ceiling above
    Status
    active
  • Lot 2 - CM/PHG/17/5532/01 Oral Products plus non-parenterals

    Signed
    30 Nov 2021
    Value
    ceiling above
    Status
    active
  • Lot 2 - CM/PHG/17/5532/01 Oral Products plus non-parenterals

    Signed
    30 Nov 2021
    Value
    ceiling above
    Status
    active
  • Lot 2 - CM/PHG/17/5532/01 Oral Products plus non-parenterals

    Signed
    30 Nov 2021
    Value
    ceiling above
    Status
    active
  • Lot 2 - CM/PHG/17/5532/01 Oral Products plus non-parenterals

    Signed
    30 Nov 2021
    Value
    ceiling above
    Status
    active
  • Lot 2 - CM/PHG/17/5532/01 Oral Products plus non-parenterals

    Signed
    30 Nov 2021
    Value
    ceiling above
    Status
    active
  • Lot 2 - CM/PHG/17/5532/01 Oral Products plus non-parenterals

    Signed
    30 Nov 2021
    Value
    ceiling above
    Status
    active
  • Lot 2 - CM/PHG/17/5532/01 Oral Products plus non-parenterals

    Signed
    30 Nov 2021
    Value
    ceiling above
    Status
    active
  • Lot 2 - CM/PHG/17/5532/01 Oral Products plus non-parenterals

    Signed
    30 Nov 2021
    Value
    ceiling above
    Status
    active
  • Lot 2 - CM/PHG/17/5532/01 Oral Products plus non-parenterals

    Signed
    30 Nov 2021
    Value
    ceiling above
    Status
    active
  • Lot 2 - CM/PHG/17/5532/01 Oral Products plus non-parenterals

    Signed
    30 Nov 2021
    Value
    ceiling above
    Status
    active
  • Lot 2 - CM/PHG/17/5532/01 Oral Products plus non-parenterals

    Signed
    30 Nov 2021
    Value
    ceiling above
    Status
    active
  • Lot 2 - CM/PHG/17/5532/01 Oral Products plus non-parenterals

    Signed
    30 Nov 2021
    Value
    ceiling above
    Status
    active
  • Lot 2 - CM/PHG/17/5532/01 Oral Products plus non-parenterals

    Signed
    30 Nov 2021
    Value
    ceiling above
    Status
    active
  • Lot 2 - CM/PHG/17/5532/01 Oral Products plus non-parenterals

    Signed
    30 Nov 2021
    Value
    ceiling above
    Status
    active

Bid statistics published by the authority

LotBidsSMEVCSEValid bid range
1 · CM/PHG/17/5532/00 Transition (Everolimus)7bids · 7 electronic———
2 · CM/PHG/17/5532/01 Oral Products plus non-parenterals124bids · 124 electronic———
3 · CM/PHG/17/5532/02 Hospital Only Products114bids · 114 electronic———

Contracting authority & participating public bodies

The NHS Commissioning Board (operating under the name of NHS England)

Contracting authorityNHS & healthcareMinistry or any other national or federal authority, including their regional or local subdivisionsHealth 2nd Floor, Rutland House, Runcorn, UK, WA7 2ESContact name, email Published organisation website ↗

Framework contractors & participating bidders

131 commercial parties on the notice · 50 awarded

The first 50 of 131 commercial parties (by name); the JSON mirror lists them all.

Show 40 more suppliers

Official documents & specifications (1)

Official links; attachments are not copied

Tender pack and attachments

  • Economic and financial selection criteriatenderEconomic and financial selection criteria